OTC: AURX · Industrial Applications and Services · 3 alerts · CIK 1091596
Share price
$1.09Close, Nov 13
Market cap
$53M
Shares outstanding
48.59MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nuo Therapeutics, Inc. filings on SEC EDGAR ↗
Nuo Therapeutics reported Q3 2026 financial results with total revenue of $1.9 million, an 80% increase year-over-year. The company highlighted strong growth in hospital-based Aurix sales and noted that final 2027 Medicare reimbursement rulings reinforce its long-term growth outlook.
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above”
David Jorden, Nuo’s Chief Executive and Financial Officer
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth.”
David Jorden, Nuo’s Chief Executive and Financial Officer
Nuo Therapeutics reported a significant revenue increase to $4.9 million for the nine months ended September 30, 2026, compared to $2.2 million in the prior year, driven by product sales and distribution fees. Despite the growth, the company remains in a stockholders' deficit and continues to rely on debt financing, including $1.175 million in net proceeds from notes payable issued during 2026.
Nuo Therapeutics Debt Financing Update with Scott M. Pittman
Nuo Therapeutics entered into an amendment to its Amended and Restated Loan and Security Agreement to close a second funding tranche of $325,000. The company has now received an aggregate of $2.0 million under the facility, with the new notes bearing 12% interest and maturing on December 31, 2028. The funding involved the joinder of three new lenders and an additional commitment from director Scott M. Pittman.